• CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
• CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
• Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
• The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
• An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties

Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks. The spotlight event (event can be accessed at https://ibn.fm/QhlSJ, presented by corporate and private client services advisors at JTC IR showcases CNS’s novel anthracycline Berubicin, which appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. Neuro-oncologist opinion leader Samuel A. Goldlust, M.D., joined CNS Pharmaceuticals CEO John Climaco for the live Web event April 14, which was recorded for on-demand access through July (https://ibn.fm/7j4DD). Dr. Goldlust currently serves as the Pitkin Chair in Neuro-Oncology and the Medical Director of the Brain and Spine Institute at the John Theurer Cancer Center, and is an investigator in CNS’s global Berubicin study. Berubicin was the drug candidate subject of a small-scale Phase 1 clinical trial in 2006 that evaluated Berubicin’s safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit (https://ibn.fm/6Llns). GBM patients in general have a median survival rate of only 14.6 months after diagnosis, which is evidence of the need for an effective treatment for the thus-far incurable cancer. Anthracyclines like Berubicin are among the most powerful chemotherapy drugs and are effective against more types of cancer than any other class of chemotherapeutic agents, according to the company. They are designed to utilize natural processes to cause deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of cell-growth enzyme topoisomerase II. The potentially pivotal global trial that is currently under way began recruiting and dosing patients in the United States with Berubicin in 21-day cycles last year, and governmental approvals in European countries are advancing efforts to begin recruitment there (https://ibn.fm/pSXOP). Ultimately, more than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.” The company expects to report an interim analysis of its results early next year when 50 percent of the patients have reached the six-month point in their dosing regimen. Primary completion of the study is anticipated by October 2024, with final completion expected by February 2025 (https://ibn.fm/4DVcX). CNS is also in the process of developing a drug candidate labeled WP1244, which uses anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than chemotherapy agent daunorubicin in stopping tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity, according to the company, making WP1244 worth evaluating for treating brain cancers, as well as pancreatic and ovarian cancers and lymphomas. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Fan Pass Live with Artist Republik and FeaturedX is creating a 360 platform with pricing that sets them apart from competitors
• The May contest on Instagram is underway, and features Grow with Us (“GWU”) campaigns to help artists build their fanbase on Spotify/Soundcloud
• In the first 100 days, positive growth has been reflected across revenue per subscriber, spend per customer, and subscriber lifetime value
• Key metrics for social media have also seen an increase across the board

In the five months since announcing the acquisition of Artist Republik (and FeaturedX), Friendable (OTC: FDBL), and its flagship offering, Fan Pass Live artist platform, has seen increased growth in several areas, including social media reach, artist recruitment, and fan subscriptions – among other metrics. The combination of services has provided Friendable with the first 360 artist platform offering, resulting in a one-of-a-kind “anti-label” movement. Other platforms advertise a complete independent artist offering, but none compare to the offering provided by Friendable through Fan Pass Live, Artist Republik, and FeaturedX. Fan Pass Live took to Instagram (@fanpasslive) to let artists know exactly what sets them apart from their competitors:

• Price: $5.00 (Single), $11.00 (Album), $14.99 (Subscription)
• Annual Fee: $0
• Royalties Paid to Artists: 100%
• IRSC and UPC: FREE
• Promotions: Social Links, Playlisting, PR, Distribution, Ticketed Live Streaming, Revenue Building, Websites, and More

Each month, Fan Pass Live offers its artists additional revenue opportunities through contests that are posted on Instagram. For May, Fan Pass Live wants to help artists grow their fanbase. The top three artists with the highest streaming time in May will win free fan growth (Grow with Us) campaigns on Spotify/Soundcloud. First place will receive a $100 GWU campaign; second place will receive a $50 GWU campaign; third place will receive a $25 GWU campaign. Additionally, when an artist promotes three streams on Instagram and tags Fan Pass Live, they can win a free promo design (https://ibn.fm/mE4wy). Recent key metrics reported by the company about the first 100 days of growth for the year (per stripe merchant reporting) included revenue per subscriber increasing by 107.3% (an average of $10.72 per subscriber), spend per customer increasing 28.3% (an average of $34.12 per customer), and subscriber lifetime value (“LTV”) increased 168.5% (an average LTV of $214.45). “The reward of seeing results continues to motivate and point our team in the right direction, as our collective efforts of testing, iterating, testing, testing, and more testing pay off,” Friendable CEO Robert A. Rositano Jr. stated (https://ibn.fm/cgGnb). “We must constantly look at the macro vision and direction, but it’s the micro-levels of detail that provide the most valuable data as we seek the next milestones in artist sign-ups, fan engagement, and conversions to purchases of all kinds, which is what the above results are showing us.” The most recently reported social media statistics show key growth for March 2022 over February 2022:

• New Customers – increased by 55.6%
• New Subscribers – increased by 38%
• Spend per Customer – increased by 5.2%
• Revenue per Subscriber – increased by 4.2%
• Subscriber Lifetime Value – increased by 23.5%
• Subscriber Churn/Cancelation Rate – decreased by 15.6%

In an April press release discussing these metrics (https://ibn.fm/55uxk), (https://ibn.fm/OSl5n), Rositano Jr. stated that “From social media to revenue and user increases, as well as steady growth in key categories, it tells us everything we need to know about the path we are on as a Company, platform, team, and community of fledgling artists, fans and investors all seeking to facilitate the launch and discovery of artists worldwide as we build a brand that stands alongside each one.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
• Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
• Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
• It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation

Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability. Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more. In March 2022, the company announced that it would begin a human clinical study, NIC-H22-1, focused on oral nicotine alternatives to replace smoking. The study would involve 36 participants and compare DehydraTECH’s nicotine pouch performance with existing brands on the market. In a previous animal study, the DehydraTECH-nicotine proved to deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls (https://ibn.fm/GI3R4). Lexaria is also in the process of a clinical human study, HYPER-H21-4, to determine the effectiveness of DehydraTECH-CBD for hypertension treatment. Involving 60 participants, this ranks as one of the most comprehensive studies undertaken by Lexaria and is a significant step for the company as it seeks Investigational New Drug (“IND”) approval by the United States Food and Drug Administration (“FDA”). Results are expected in Q3 2022 (https://ibn.fm/rLyN3). Lexaria has also made significant progress using its technology for the enhanced delivery of antiviral drugs. On April 26, 2022, it received its 25th patent granted worldwide in what Chris Bunka, the Chief Executive Officer (“CEO”) of the company, referred to as “Another validation of the versatility of our DehydraTECH drug delivery technology” (https://ibn.fm/OhJlO). Earlier in the year, Lexaria also announced commencing the first phase of its epilepsy research program, EPIL-A21-1. The study would assess the seizure-inhibiting activity of CBD administered via the company’s DehydraTECH technology. More specifically, Lexaria aimed to compare its technology to the only FDA-approved CBD-based seizure medication Epidiolex, used to treat seizures associated with two rare forms of pediatric epilepsy- Lennox-Gastaut syndrome and Dravet syndrome (https://ibn.fm/7CnzW). All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so, it is looking to tap into various markets, including but not limited to oral cannabinoids, oral mucosal nicotine, antivirals, human hormones, dementia, rheumatoid disease and diabetes. Lexaria’s management hopes that before the end of the 2022 calendar year, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation to steer the conversation forward and allow for the greater adoption of DehydraTECH. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Dynamic Global Events (“DGE”) invites you to the 2nd Promotional Review Committee (“PRC”) Performance Optimization Summit, regarded as the largest, most detailed PRC conference available. Slated for May 23-25, the three-day online livestream event is designed for all the cross-functional professionals working on review teams, including legal, medical communications, public relations, marketing, product management, brand management, editors, compliance, art, scientific communications, and more. The summit provides PRC best practices for team management and cooperation, maintaining regulatory compliance, and adapting to new technologies and platforms. Promotional review professionals face many challenges as they craft fair and accurate product messages that must conform to all regulations.  Gathering multiple rounds of feedback in a collaborative environment, making sure ad agencies have understood all their guidelines, and anticipating the response of subjective regulatory reviewers was already challenging enough – and now in a post-COVID setting, most of these committees are not even meeting in-person. So, the return of the industry’s largest and most trusted PRC learning event could not have happened at a better time. Last year’s conference was acclaimed as “an excellent event for finding out how others are doing things in the industry” (Head, Promotional Excellence, Sanofi) that featured “topics that were of value and speakers who were very knowledgeable on the topics they presented” (Director, U.S. Advertising & Promotion, AbbVie). (https://ibn.fm/8hOd3). So, attendees at this year’s summit are definitely in for a treat. Attendees will hear from vice presidents, lead counsels, directors, and department heads responsible for regulatory affairs, advertising, promotion, and labeling divisions.   Drawn from organizations such as Turning Point Therapeutics, Takeda, Sanofi, Kyowa Kirin, Abbvie, Otsuka, Merz Aesthetics, Mirati Therapeutics, Merck, Sobi, and more, the 25 featured speakers will take part in panel discussions as well as single-person and joint presentations anchored in three main themes, according to the event brochure. Some of this year’s all-new agenda topics, added to meet audience requests, include PRC strategies for modular content, artificial intelligence, celebrity endorsements, upgrading team training, empowering coordinators, and much more. Overall, the summit will:

• Provide a roadmap for building and maintaining a core claims compendium
• Offer important tactics for digital asset management
• Focus on review and submission methods for modular content
• Discuss detailed compliance strategies for speaker bureaus, celebrity endorsements, streaming video, payer communications, investor media, and more
• Provide key learnings for entire teams

To learn more, please visit https://dgevents.com/event/promotional-review-committee-performance-optimization/

ND Supplies presents the 3-day O’Cannabiz Conference Expo & Awards, June 1-3, 2022, at the Toronto International Centre this year. Voted the No. 1 Cannabis Event in Canada by High Canada Magazine, the O’Cannabiz International Conference returns as an in-person event, after being canceled last year. The event organizers are thankful to the partners, sponsors, and exhibitors for their patience and co-operation. The event is being touted as the most sort after cannabis conference in North America featuring Cannabis trade shows, retail summits, awards functions along with global-level networking opportunities among the veterans and dignitaries of the cannabis spectrum in Canada. Cannabis vendors, creatives, enthusiasts, researchers, regulators, and activists are invited to attend this 3-day event that will witness veterans who travel from the length and breadth of the region to attend this event. Attendees will a true cannabis business experience at this conference that covers a broad spectrum of diverse topics on cannabis offering valuable learning sessions. In a power-packed business-to-business show, young businesses, and aspiring entrepreneurs can leverage this huge platform to build long-term business relations and establish networking ties with peers and thought leaders in the only G7 country to legalize both the medicinal and recreational use of cannabis. At the exhibit portion of the trade show, attendees can visit the exhibitor booths lined in the 50,000-square-foot expo hall, showcasing different facets of the cannabis industry, products, and novel ideas for people to learn and understand. Investors in search of lucrative business opportunities can explore and discover enterprising talent at these booths. The three days of networking opportunities will foster lifetime connections amongst the members of the cannabis community. 3,500+ attendees are expected to grace the event and participate in the 70+ interactive sessions, on a mammoth stage shared by 180+ industry leaders who will reside as speakers to impart valuable tips and strategies on vital topics like cannabis trading and laws, extraction & compliance in Canada., Attendees will receive a grand welcome at the Red Carpet Royalty Cocktail Reception. As a part of the O’Cannabiz Conference, on June 1st, 2022, the 2nd Annual O’Cannabiz Awards Dinner Gala will be hosted by CBC’s Gerry Dee, at Toronto’s Casa Loma to felicitate the dignitaries of the cannabis and recognize their contribution by honoring them with excellence awards. Marijuana activists Tommy Chong and Steve De Angelo will be presented with a Lifetime Achievement Award, and all other award winners will be announced live at the Gala. Enthusiasts, retailers and budtenders can check out the latest retail products at the Retail Summit, dedicated to the point-of-sale side of the cannabis industry. To learn more, please visit https://ocannabiz.com/.

FinovateSpring is a CPE and CPD certified event, hosted by Finovate Group that organizes fintech seminars and events for the last 10 years. This year, FinovateSpring is coming to San Francisco, California, as a live in-person event on May 18-20, 2022. For the first time since 2019, the annual spring fintech conference will feature live, in-person demos, in-person speakers, discussions, panels, and global thought leaders of the financial technology spectrum. This event will be hosting 1,100+ senior attendees, more than 50% of whom are from financial institutions. As a bonus, the show will be graced by representatives of the top 10 banks in the U.S. To attend the event, there will be 50+ demoers, 100+ speakers, 270+ financial institutions, 200+ C-level attendees, and 100+ media personnel, who will cover the event. Finovate events are attended by influential personas of the fintech arena namely investors, decision-makers, regulators, and innovators leading the fintech revolution, who attend these events year after year. They have substantial authority and offer key insights into the future of financial services technology. From showcasing your new fintech solution in front of the Finovate community to collaborations, long-term partnerships, and funding along with making new clientele and getting expert feedback, the FinovateSpring has plenty to offer its attendees. Get live demos from startups, two startup-booster opportunities are being floated this year to help startups gain visibility on this forum. New formats like Fintech Fight Club and Finovate Unicorn Power Panel, along with 30 companies making their Finovate debuts, are some exciting opportunities available for new and small-scale entrepreneurs. Along with the networking scope, attendees get two days of live, in-person fintech demos and 3-days of insightful keynotes, fireside chats, discussions, and debates. The opening speech will be given by Greg Palmer, Vice President, Finovate. Some important keynote discussion and boardroom topics include

• How to win the war for fintech talent-attracting the right manpower
• Why do digital transformation projects generally fail- how to prevent the fallout
• Why diversity matters
• The three C’s of innovation- culture, customer, and connection
• Harnessing new tech to meet the needs of businesses and consumers
• Financial cybercrime and how new technology can harness the fraud

Organizers are taking the requisite steps to comply with COVID-19 guidelines and conduct the Finovate event in a sustainable and socially responsible manner. To learn more, please visit https://informaconnect.com/finovatespring/.

• Visa will provide its extensive network of payment experts to assist LQwD (and other fintech companies) who join the program
• LQwD is currently operating ten global nodes on the Bitcoin Lightning Network – France, England, Sweden, Singapore, Italy, Indonesia, Germany, Ireland, the US, and India
• LQwD launched its proprietary PaaS platform in November 2021, working to lower transaction fees and facilitate faster transaction times
• The cryptocurrency market is expected to reach a value of US $4.94 billion by 2030

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive the adoption of Bitcoin, has announced that it has joined Visa’s (NYSE: V) Fintech Fast Track Program. By working with Visa, a world leader in digital payments, LQwD can accelerate bringing Bitcoin to the masses through its subsidiary Coincurve.com, a virtual currency platform, along with its proprietary platform as a service (“PaaS”) offering and global routing nodes (https://ibn.fm/G1yGM). The Visa Fintech Fast Track Program was established for fintech companies to create new and innovative payment solutions through partnership, collaboration, and investment. The program offers fintech companies a payments path that is right for their current endeavors – including the idea, funding, and growth stages. Visa provides these companies with startup incentives, faster onboarding, and dedicated expertise and support. The Visa Fintech North American Fast Track offers:

• Smooth onboarding to Visa’s global network
• Lower expenses from Visa and selected enablement partners
• Referrals to partners based on need
• Payment experts providing the hands-on support and guidance needed to get fintechs up and running

To join the Fast Track Program, LQwD had to fill out an application and meet certain stipulations implemented by Visa, after which it underwent a review process to determine if it qualified for the program. Since approval, LQwD has been able to onboard with Visa and implement the go-to-market strategy. “By joining Visa’s Fast Track program, exciting fintech companies like LQwD gain valuable access to Visa experts, technology, and resources. Fast Track lets us provide new resources that rapidly growing companies need to scale with efficiency,” Visa’s SVP and Global Head of Fintech, Terry Angelos, commented. Shone Anstey, CEO of LQwD, underlined that this was an exciting opportunity for the company. “Our direct relationship with Visa now gives LQwD the advantage of accessing their growing partner network, as well as experts in the payments space. It’s a big benefit,” he added. LQwD currently has ten global nodes operational on the Lightning Network, including France, England, Sweden, Singapore, Italy, Indonesia, Germany, Ireland, the US, and the most recently launched node – India. Altogether, LQwD already has a capacity of over 10 BTC and is growing consistently. In November 2021, in coordination with the launch of its first node (US-West), the company also launched its PaaS platform – https://lqwd.tech/. Since then, the company has focused on scaling the Lighting Network and making Bitcoin transactions possible on a global level with lower fees and faster settlement times, amid growing interest in cryptocurrencies and the Lightning Network worldwide. According to Allied Market Research, the cryptocurrency market was valued at US $1.49 billion in 2020. Growing at a CAGR of 12.8%, the market is expected to reach US $4.94 billion by 2030. The primary drivers for growth are the growing acceptance of these currencies as legal tender and technological advancements (https://ibn.fm/2TTPB). For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Intellectual property theft costs the United States $225-600 billion every year
• Crime, in general, has a negative economic impact of over $2 trillion annually
• Knightscope, through its ASRs, seeks to remedy the situation by offering 24/7/365 security, thereby securing clients’ physical and intellectual property
• The effectiveness of these ASRs has seen a San Francisco Bay Area biotech real estate development subscribing to two K5 ASRs and one K2 ASR

Approximately 12,000 intellectual property cases are filed in federal court annually. Every year, intellectual property theft costs the United States between $225 and $660 billion, for a sector that accounts for 27.7% of jobs in the country (https://ibn.fm/Afduy). Markedly, there is a need to protect companies’ intellectual property just as there is to protect physical property, such as with chemical or biotech companies threatened with the theft of key research samples and the theft or damage of advance equipment. One company helping enterprises secure themselves on all fronts is Knightscope (NASDAQ: KSCP). Known for developing autonomous security capabilities, Knightscope has products designed to cater to public institutions and commercial business operations. Its Autonomous Security Robots (“ASRs”) offer comprehensive property monitoring and reporting on a 24/7/365 basis. They have so far clocked over one million hours in the field and won security contracts that cover multiple time zones, seasons, and organizations in the U.S. Knightscope is committed to disrupting the $500 billion security industry, and hopes to do so by offering an overall package that secures companies’ physical and intellectual property, and protecting the safety of employees, in a more cost effective manner than with traditional approaches. The effectiveness of Knightscope’s ASRs and their track record have grown the company’s client list, which includes multiple Fortune 1000 companies. The latest addition to that list is a San Francisco Bay Area biotech real estate development that has subscribed to two of the company’s K5 ASRs and one K2 ASR. The move is designed to enhance the client’s amenity-rich real estate project while underscoring public safety in a highly regulated environment (https://ibn.fm/mIwAE). Knightscope will patrol a parking garage while also monitoring the common areas with this arrangement. This will protect the client’s physical property and its intellectual property under development at this high-tech facility. It will also provide additional protection for the employees working at the facility. Knightscope is leading the industry in integrating autonomous security solutions, currently comprising the K1 stationary machine, a K3 indoor machine, and a K5 outdoor machine. With more companies subscribing to these solutions, Knightscope is not only bringing the US closer to being the safest nation in the world but is also creating incredible value for its shareholders. For more information, visit the company’s website at www.Knightscope.com. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• EverGen Infrastructure reported their Q4 ‘21 quarterly results on April 21, 2022
• The company reported 4Q21 revenues of CAD $2.693 million, +39% QoQ
• EverGen simultaneously reported that their 4Q21 EBITDA was impacted by the flooding event that took place late last year, however revealed that their facilities had come back online as of early March 2022, and business interruption insurance would be recognized in 2022
• The company also revealed a series of additions and changes within their executive management team

EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based Renewable Natural Gas owner and operator, published its fourth quarter 2021 quarterly results on Thursday 21 April 2022 (https://ibn.fm/bXKQH). EverGen reported fourth quarter revenues of CAD $2.693 million, a figure which was up 39% quarter-over-quarter, largely resulting from higher volumes of incoming organic feedstock resulting from the flooding events which took place in Canada’s Abbotsford and Sumas Prairie regions. Nonetheless, the flooding events also contributed to a temporary shutdown of EverGen’s FVB facility on November 15, 2021, an extraordinary event which impacted the company’s net income and EBITDA for the quarter. EverGen Infrastructure revealed that their operations had now successfully recovered from the flood impact, with their FVB facility back online as of March 2, 2022. Moreover, the company also reported that it had recovered upwards of $1.7 million of insurance proceeds, representing a progress payment relating to lost revenues and additional expenses incurred from the flooding events. The company now intends to recover further insurance proceeds related to the event throughout 2022, resulting in a deferral of positive Adjusted EBITDA which would have otherwise been recognized in the fourth quarter of 2021. EverGen had a transformational year in 2021, which saw the company assemble their core British Columbia-based portfolio, acquire subsidiary Fraser Valley Biogas, and lead the initial public offering of the company – measures which taken in unison have served to position EverGen as one of Canada’s premier renewable natural gas (“RNG”) infrastructure platforms. The company also announced a series of managerial additions and changes within the executive team. After successfully leading EverGen’s initial acquisitions and August 2021 IPO, Mischa Zajtmann, President of EverGen will transition into the role of Chief Operating Officer, with the goal of overseeing the company’s technical operations along with the development and integration of ongoing growth projects. Separately, EverGen also welcomed Jamie Betts, VP of Operations, and Sean Hennessy, VP of Finance, recent additions set to assist the company as it continues to expand its RNG operations as well as to further its inorganic growth initiatives moving forward. Betts, an engineer by training, joins EverGen as VP of Operations with over 35 years of experience in multinational energy and waste management companies, including, more recently, the positions of VP of Engineering at Miller Waste Systems Inc. and Project Director at Husky Energy. Meanwhile, Hennessy, a chartered accountant, joins EverGen as VP of Finance with over 15 years of finance and accounting related experience, including the positions of Director of Corporate Reporting for Altera Infrastructure, a global energy infrastructure group and a Brookfield Business Partners portfolio company, and Director of Financial Reporting for a clean technology company. Going forward, EverGen have outlined their onward growth plans, with the company’s recently announced letter of intent to acquire a 67% interest in GrowTec, an Alberta based biogas facility, serving as the cornerstone of their plan to expand into new geographic jurisdictions and broaden their presence within the Canadian RNG industry. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Golden Matrix Group is a gaming technology and e-sports company, operating its own gaming IP alongside providing white-label gaming platforms for third-parties
• Golden Matrix reports Revenues of $8,877,105 & net income of $349,379 in the quarter ending January 2022, their 14th consecutive quarter of profitability
• The company have based their profitability on minimizing user acquisition costs and maximising lifetime customer value
• Golden Matrix, via its successful R Kings B2C Tournament platform, has devised a new method to attract customers through the use of online prize draws, drawing in upwards of 90,000 new users per quarter

The onset of the pandemic hastened an already existing shift away from location-based casinos towards online gaming; in fact, a recent study has forecast the online gambling market to reach US$217.3 billion by 2027, representing a CAGR of 11.5 percent between 2020 and 2027 (https://ibn.fm/hEszL). Las Vegas-based Golden Matrix Group (NASDAQ: GMGI), an established gaming technology and e-sports company which owns and operates online gaming IP as well as white-label gaming platforms for third-party customers, has sought to capitalize on the ongoing shift, a change in customer behavior which has been further accelerated by a burgeoning younger and tech-savvy consumer demographic. The company recently revealed that it had recorded revenues of $8.88 million for the quarter ending January 31, 2022, an increase for 355% over the same period a year ago. Golden Matrix simultaneously reported net income of $349,379 over the course of the three-month period, extending a remarkable stretch which has now seen the gaming company record its 14th consecutive profitable quarter. A key trait which has characterized Golden Matrix Group’s resolute pursuit of profitability comes down to the company’s innovative approach towards customer acquisition costs (“CAC”) and lifetime value (“CLV”) – a strategy which has filtered through into their recent acquisitions (https://ibn.fm/H46E1). In December 2021, Golden Matrix entered into a purchase agreement to acquire an 80 percent controlling interest in UK-based R Kings Competitions Ltd., a leading independent online competition company (https://ibn.fm/hVxti). Through their combination with R Kings Competitions, Golden Matrix have pioneered a system by which new users can gain access to a prize draw after responding correctly to a question – a competition which Golden Matrix CEO, Brian Goodman, has credited with attracting upwards of ninety thousand new players a quarter at relatively low cost. Going forward, the company anticipates rolling out their tournament methodology into new geographies and languages – recently revealing that they had applied for a Mexican gaming permit which would allow them to attract new users and offer online gaming within the country. Having already gained considerable market share within the B2B market through the roll-out of their GM-X system, a gaming system designed to enable online providers to gain access to a broad array of over 10,000 games from over 25 developers, Golden Matrix Group are now seeking to grow their presence within the B2C. CEO, Brian Goodman recently divulged that the company were pursuing a series of acquisitions within the B2C gaming space, a measure designed to assist Golden Matrix to better monetize their burgeoning customer base. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI